e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Novel drugs and biomarkers in respiratory medicine
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Safety and efficacy of 7% hypertonic saline in patients with bronchiectasis
C. Hodgekiss, J. Slough, T. Capstick, D. Peckham, I. Clifton (Leeds, United Kingdom)
Source:
Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Session:
Novel drugs and biomarkers in respiratory medicine
Session type:
Thematic Poster Session
Number:
745
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Hodgekiss, J. Slough, T. Capstick, D. Peckham, I. Clifton (Leeds, United Kingdom). Safety and efficacy of 7% hypertonic saline in patients with bronchiectasis. Eur Respir J 2013; 42: Suppl. 57, 745
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Effects of hypertonic saline on sputum clearance in patients with bronchiectasis
Source: International Congress 2016 – Best abstracts on innovative outcomes and novel interventions in respiratory physiotherapy
Year: 2016
Audit of once daily nebulised hypertonic 6% saline (HTS) in adult bronchiectasis
Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Year: 2010
A cross-over study to compare the Lung Flute™ to hypertonic saline inhalation about the performance of inducing sputum for the diagnosis of pulmonary tuberculosis
Source: International Congress 2015 – Management of TB: a patient focus
Year: 2015
Clinical surveys with nebulised hypertonic saline (HS) in CF children
Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis
Year: 2020
LATE-BREAKING ABSTRACT: Safety and efficacy of inhaled mannitol over 12 months in high-risk patients with non-CF bronchiectasis
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
A single blind study to compare nebulised hypertonic saline (7%) and normal saline (0.9%) as an adjunct to physiotherapy airway clearance in patients with bronchiectasis
Source: Eur Respir J 2005; 26: Suppl. 49, 304s
Year: 2005
Inhalation therapy with hypertonic saline (3%) – A treatment option for airway disease in children?
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015
Nebulized saline treatment in patients with concomitant asthma and bronchiectasis
Source: Virtual Congress 2021 – Bronchiectasis and pleural infection
Year: 2021
Effectiveness and safety of hypertonic saline inhalation combined with exercise training in patients with chronic obstructive pulmonary disease: a randomized trial
Source: Annual Congress 2009 - Improving outcome through exercise training or physiotherapy interventions
Year: 2009
Efficacy of administration of 0.02% solution of decamethoxine via nebulizer in patients with infectious exacerbations of COPD
Source: Annual Congress 2013 –COPD treatment
Year: 2013
Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013
Safety and efficacy of emphysematous lung sealant (ELS) therapy for advanced emphysema out to 2 years
Source: Annual Congress 2013 –Bronchoscopic treatment of COPD and asthma: where are we going?
Year: 2013
Nebulised 7% hypertonic saline improves health related quality of life in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2011 - Chest physiotherapy and breathing retraining
Year: 2011
The efficacy and tolerability of inhaled hypertonic saline in children with cystic fibrosis
Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis
Year: 2020
Effects of dornase alfa and hypertonic saline on gas mixing in lung periphery in children with cystic fibrosis
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014
Success rate of sputum induction in the Leicester paediatric severe asthma clinic using nebulised hypertonic saline: A 2-year review
Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring
Year: 2010
Preliminary results of study of bronchoscopic hot saline ablation (BHSA) treatment, in emphysematous lung disease
Source: International Congress 2015 – Bronchoscopic treatment of COPD and asthma: valves, coils, thermoplastics and something more
Year: 2015
Pulmonary targeted antibiotics in bronchiectasis; inhalers vs. nebulisers. A qualitative and quantitative assessment of patients’ attitudes
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016
Safety and efficacy of ectoine inhalation solution in patients with inflammation and airway obstruction: The EFECT study
Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use
Year: 2012
Comparison of inspiratory flow rates using an innovative dry powder inhaler (DPI) in patients with mild–severe asthma and severe COPD
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept